Stockreport

Data Safety Monitoring Board Confirms Triple Negative Breast Cancer as the Target Patient Population for Development of NeuVax™ (nelipepimut-S) in Combination with Trastuzumab (Herceptin®)...

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF Data Safety Monitoring Board met on October 15, 2018 for final analysis Interim and final results of the Phase 2b study to be presented on Monday, October 22, 2018 duri [Read more]